Clinical Trial

Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 20, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study retrospectively analyzes the clinical data of HER2-low breast cancer (IHC 1+/2+ and FISH-negative) patients treated with sequential antibody-drug conjugates (ADCs). Key variables include patient demographics, tumor characteristics, ADC regimens (e.g., trastuzumab deruxtecan, sacituzumab govitecan), treatment sequencing, survival outcomes, and safety profiles. Genomic data (e.g., HER2 expression dynamics, TROP2 levels) are integrated to explore resistance mechanisms and prognostic biomarkers.mechanisms. This study aims to investigate the efficacy of different ADC sequential regimens in HER2-low breast cancer patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-10.
Trial Details
NCT Number NCT06877416
Lead Sponsor Sun Yat-sen University
Conditions Antibody-drug Conjugates, HER2-low Breast Cancer, Breast Neoplasms
Enrollment 700 participants
Start Date 2020-01-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-20